Skip to content

To evaluate the efficacy and safety of two microstructured eyeglasses in delaying the progression of myopia

To evaluate the efficacy and safety of two microstructured eyeglasses in delaying the progression of myopia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102941
Enrollment
Unknown
Registered
2025-05-22
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Interventions

Group A:Wear Beyo Little Sunflower Scattering Myopia Management Lens
Group B:Wear Beyue myopia astigmatism dual control lenses
Group C:Wear DIMS spectacles

Sponsors

Wenzhou Medical University Affiliated Eye and Vision Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 13 Years

Inclusion criteria

Inclusion criteria: 1) Age >= 7 years old and = -Between 5.00D, astigmatism = 5.0 5) Voluntarily participate in this clinical trial and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Those who have a history of eye trauma or intraocular surgery that affects the wearing of frame glasses 2.Abnormal intraocular pressure (intraocular pressure21mmHg) 3.Combined with other eye diseases such as uveitis, various inflammations, glaucoma, cataracts, and any eye lesions that affect visual function. 4.Patients determined by researchers to be ineligible for inclusion: (1) Patients with systemic diseases that lead to low immunity (such as diabetes, Tang's syndrome Syndrome, rheumatoid arthritis, mental illness, or other diseases that researchers consider unsuitable for wearing frame glasses (2) Individuals who have participated in non ophthalmic drug clinical trials within the past three months and have previously participated in ophthalmic drug or device clinical trials (3) Have used any myopia control products, such as corneal reshaping lenses, myopia prevention and control glasses, etc, Used atropine and other medications, but not including dilating drugs used during refractive examinations (4) Individuals who are unable to undergo regular eye examinations (5) The researchers determined that other situations could not be included in the selection.

Design outcomes

Primary

MeasureTime frame
Changes in axial length (AL) from baseline within ± 30 days of December;Changes in axial length (AL) from baseline within ± 30 days of June;

Secondary

MeasureTime frame
Objective refraction equivalent spherical power (SER) changes compared to baseline after 12 months ± 30 days of ciliary muscle paralysis;Objective refraction equivalent spherical power (SER) changes compared to baseline after 6 months ± 30 days of ciliary muscle paralysis;

Countries

China

Contacts

Public ContactJinlin Ye

Wenzhou Medical University Affiliated Eye and Vision Hospital

yejinlin@hotmail.com+86 135 8796 9799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026